Drugs / SPK-8011QQ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07226206 | Jul 2026 → Jul 2031 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Genentech, Inc. | Results Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗
Pre-clinical data on Genentech’s next-generation investigational AAV gene therapy, show significantly enhanced hemostatic potency compared with SPK-8011 (dirloctocogene samoparvovec) in ex vivo and in vivo mouse models. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Genentech, Inc. | Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPK-8011QQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226206 ↗ |
| Route | Intravenous | “Participants will receive IV SPK-8011QQ” NCT07226206 ↗ |